<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Med</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Med</journal-id><journal-id journal-id-type="pmc-domain-id">2745</journal-id><journal-id journal-id-type="pmc-domain">jclinmed</journal-id><journal-id journal-id-type="publisher-id">jcm</journal-id><journal-title-group><journal-title>Journal of Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2077-0383</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12429806</article-id><article-id pub-id-type="pmcid-ver">PMC12429806.1</article-id><article-id pub-id-type="pmcaid">12429806</article-id><article-id pub-id-type="pmcaiid">12429806</article-id><article-id pub-id-type="doi">10.3390/jcm14176241</article-id><article-id pub-id-type="publisher-id">jcm-14-06241</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Review of Current Management of Myocardial Infarction</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Saha</surname><given-names initials="T">Trisha</given-names></name><xref rid="af1-jcm-14-06241" ref-type="aff">1</xref><xref rid="fn1-jcm-14-06241" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Soliman-Aboumarie</surname><given-names initials="H">Hatem</given-names></name><xref rid="af2-jcm-14-06241" ref-type="aff">2</xref><xref rid="af3-jcm-14-06241" ref-type="aff">3</xref><xref rid="c1-jcm-14-06241" ref-type="corresp">*</xref><xref rid="fn1-jcm-14-06241" ref-type="author-notes">&#8224;</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Asher</surname><given-names initials="E">Elad</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-jcm-14-06241"><label>1</label>Bloomsbury Campus, University College London Medical School, 74 Huntley St, London WC1E 6DE, UK; <email>trisha.saha.20@ucl.ac.uk</email></aff><aff id="af2-jcm-14-06241"><label>2</label>Department of Anaesthetics and Cardiothoracic Critical Care, Harefield Hospital, Hill End Road, Uxbridge, London UB9 6JH, UK</aff><aff id="af3-jcm-14-06241"><label>3</label>School of Cardiovascular and Metabolic Medicine and Sciences, King&#8217;s College London, Denmark Hill, London SE5 9RS, UK</aff><author-notes><corresp id="c1-jcm-14-06241"><label>*</label>Correspondence: <email>hatem.solimanaboumarie@nhs.net</email></corresp><fn id="fn1-jcm-14-06241"><label>&#8224;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>04</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>14</volume><issue>17</issue><issue-id pub-id-type="pmc-issue-id">496787</issue-id><elocation-id>6241</elocation-id><history><date date-type="received"><day>13</day><month>6</month><year>2025</year></date><date date-type="rev-recd"><day>22</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>25</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 11:25:14.803"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jcm-14-06241.pdf"/><abstract><p>Myocardial infarction (MI), commonly known as a heart attack, remains a leading cause of morbidity and mortality worldwide. It arises from a sudden cessation of coronary blood flow, most often due to plaque rupture and subsequent thrombus formation. Over the years, significant advances in the understanding, diagnosis, and treatment of MI have transformed patient outcomes. This review explores the current approaches to the management of myocardial infarction, highlighting evidence-based practices, recent advancements, and ongoing challenges in optimising care across various healthcare settings.</p></abstract><kwd-group><kwd>myocardial infarction</kwd><kwd>management</kwd><kwd>cardiovascular disease</kwd><kwd>STEMI</kwd><kwd>NSTEMI</kwd><kwd>ACS</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-jcm-14-06241"><title>1. Introduction</title><p>Myocardial infarction (MI), commonly known as a heart attack, remains a leading cause of morbidity and mortality worldwide [<xref rid="B1-jcm-14-06241" ref-type="bibr">1</xref>]. It arises from a sudden cessation of coronary blood flow, most often due to plaque rupture and subsequent thrombus formation. Over the years, significant advances in the understanding, diagnosis, and treatment of MI have transformed patient outcomes. This review explores the current approaches to the management of myocardial infarction, highlighting evidence-based practices, recent advancements, and ongoing challenges in optimising care across various healthcare settings.</p><p>Acute coronary syndrome (ACS) encompasses a range of conditions, including ST-elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI), and unstable angina. The latter two are distinguished primarily through cardiac biomarker analysis. As a symptomatic manifestation of coronary heart disease (CHD), ACS contributes to an estimated 9 million deaths globally each year [<xref rid="B2-jcm-14-06241" ref-type="bibr">2</xref>] and is responsible for 12% loss of disability-adjusted life-years worldwide [<xref rid="B3-jcm-14-06241" ref-type="bibr">3</xref>]. Risk factors for acute MI can be categorised into non-modifiable and modifiable groups, as illustrated in <xref rid="jcm-14-06241-f001" ref-type="fig">Figure 1</xref>. Beyond the immediate infarction, MI can result in lasting myocardial damage and a cascade of complications due to impaired systolic and diastolic functions. Therefore, timely reperfusion and the rapid restoration of coronary blood flow remain critical in improving both short- and long-term outcomes [<xref rid="B4-jcm-14-06241" ref-type="bibr">4</xref>].</p></sec><sec id="sec2-jcm-14-06241"><title>2. Diagnosis</title><p>Patients may present with a range of acute symptoms, such as chest pain radiating to the jaw/left arm, tightness, burning, or a sensation of heaviness, raising suspicion for ACS [<xref rid="B4-jcm-14-06241" ref-type="bibr">4</xref>,<xref rid="B5-jcm-14-06241" ref-type="bibr">5</xref>]. A key priority is distinguishing cardiac from non-cardiac causes of chest pain through a thorough history and clinical examination to prevent misdiagnosis or delays in initiating appropriate treatment. Older adults, individuals with diabetes, and female patients may present with atypical or non-specific symptoms, necessitating a heightened index of suspicion [<xref rid="B4-jcm-14-06241" ref-type="bibr">4</xref>].</p><p>On examination, patients may appear visibly distressed and diaphoretic, often exhibiting tachycardia or other arrhythmias suggestive of underlying electrical disturbances. In cases of aortic dissection, asymmetrical pulses or blood pressure differences among limbs, along with severe back pain, may be present. Fever and tachypnoea can indicate a systemic inflammatory response. Elevated jugular venous pressure and distended neck veins suggest right ventricular failure and raised central venous pressure. Additionally, lateral displacement of the apical impulse and a soft first heart sound (S1) on auscultation may be noted. Pulmonary findings such as wheezing or crackles point to pulmonary oedema or congestive heart failure, often accompanied by bilateral peripheral oedema. Abdominal tenderness may suggest alternative diagnoses, including pancreatitis or gastritis [<xref rid="B1-jcm-14-06241" ref-type="bibr">1</xref>,<xref rid="B4-jcm-14-06241" ref-type="bibr">4</xref>,<xref rid="B5-jcm-14-06241" ref-type="bibr">5</xref>].</p><p>The resting 12-lead ECG serves as the first-line diagnostic investigation in the evaluation of patients with ACS, enabling differentiation between STEMI from NSTEMI and unstable angina. Current guidelines recommend that an ECG be performed immediately and interpreted within 10 min of the patient&#8217;s arrival [<xref rid="B4-jcm-14-06241" ref-type="bibr">4</xref>,<xref rid="B6-jcm-14-06241" ref-type="bibr">6</xref>,<xref rid="B7-jcm-14-06241" ref-type="bibr">7</xref>]. If STEMI is confirmed by persistent ST-segment elevation, alongside a raised troponin, prompt activation of the catheterisation laboratory for primary percutaneous coronary intervention (PCI) is essential. If STEMI is suspected, patients should be promptly triaged for emergency reperfusion without waiting for biomarkers [<xref rid="B8-jcm-14-06241" ref-type="bibr">8</xref>]. In these cases, the interval from first medical contact to device activation should ideally be under 90 min [<xref rid="B9-jcm-14-06241" ref-type="bibr">9</xref>]. Moreover, patients with ACS complicated by cardiogenic shock or haemodynamic instability require immediate revascularisation of the culprit vessel via PCI or coronary artery bypass graft (CABG), regardless of symptom onset timing [<xref rid="B10-jcm-14-06241" ref-type="bibr">10</xref>].</p><p>New ST elevation in two contiguous leads suggests ongoing coronary artery occlusion. Lead grouping consists of anterior/septal (V1&#8211;V4), inferior (II, III, and aVF), lateral (I, aVL, and V5&#8211;V6), posterior (V7&#8211;V9), and right ventricular, as shown in <xref rid="jcm-14-06241-f002" ref-type="fig">Figure 2</xref> [<xref rid="B4-jcm-14-06241" ref-type="bibr">4</xref>,<xref rid="B11-jcm-14-06241" ref-type="bibr">11</xref>]. Criteria include &#8805;2.5 mm in men &lt; 40, &#8805;2 mm in men &gt; 40, and &#8805;1.5 mm in women regardless of age. This may be accompanied by &#8805;1 mm ST elevation in other leads, provided there is no left ventricular hypertrophy or left bundle branch block. STEMI is typically marked by convex ST elevation with reciprocal ST depression, helping distinguish it from pericarditis. STEMI equivalents include posterior MI (ST depression with tall R waves in V1&#8211;V3) and left main occlusion (widespread ST depression with ST elevation in aVR).</p><p>Cardiac troponin, preferably high-sensitivity (hs-cTn), is the most specific biomarker for MI [<xref rid="B12-jcm-14-06241" ref-type="bibr">12</xref>,<xref rid="B13-jcm-14-06241" ref-type="bibr">13</xref>]. If initial troponin levels are inconclusive, hs-cTn should be remeasured within 1&#8211;2 h or at 3&#8211;6 h for conventional cardiac troponin assays [<xref rid="B14-jcm-14-06241" ref-type="bibr">14</xref>]. These play a critical role in distinguishing NSTEMI from unstable angina, the latter lacking evidence of myocardial necrosis. The troponin I and T isoforms typically peak around 12 h after onset and remain elevated for up to 7 days. If troponin levels remain below the 99th percentile, the diagnosis leans towards unstable angina, in contrast to the characteristic rise and fall observed in NSTEMI [<xref rid="B15-jcm-14-06241" ref-type="bibr">15</xref>,<xref rid="B16-jcm-14-06241" ref-type="bibr">16</xref>]. ECG findings in NSTEMI can vary widely, ranging from transient ST-segment elevation or depression to hyperacute or biphasic T waves, T wave inversions, or even a completely normal ECG, highlighting the importance of serial testing and clinical correlation [<xref rid="B17-jcm-14-06241" ref-type="bibr">17</xref>]. Acute myocardial injury is defined by a rise and/or fall in cTn above the 99th percentile URL, accompanied by clinical evidence of acute myocardial ischaemia.</p><p>According to the Fourth Universal Definition of Myocardial Infarction, MI can be classified into five types. Type 1 is spontaneous MI due to atherosclerotic plaque rupture, while Type 2 results from an oxygen supply&#8211;demand mismatch without acute coronary thrombosis, prevalent in critically ill and elderly patients. Type 3 refers to sudden cardiac death with presumed MI before biomarker analysis/confirmation. Type 4 encompasses PCI-related infarctions, as follows: Type 4a (troponin rise &gt;5&#215; the 99th-percentile URL with new evidence of myocardial ischaemia), Type 4b (stent thrombosis), and Type 4c (restenosis). Finally, Type 5 is associated with coronary artery bypass grafting [<xref rid="B18-jcm-14-06241" ref-type="bibr">18</xref>]. In NSTEMI patients undergoing PCI, recognising Type 4a and Type 5 periprocedural infarctions has been highlighted as key to aid risk stratification, carrying significant prognostic implications [<xref rid="B19-jcm-14-06241" ref-type="bibr">19</xref>].</p></sec><sec id="sec3-jcm-14-06241"><title>3. Initial Treatment</title><p>ECG-guided risk stratification allows for timely triage and optimises treatment initiation. Patients diagnosed with STEMI should be urgently transferred to the nearest PCI centre. In the absence of ST elevation, those with ongoing ischaemic symptoms consistent with NSTEMI should be managed according to the NSTEMI pathway to prevent complications.</p><p>In the acute setting, the priority for both STEMI and NSTEMI patients is the prompt administration of a 150&#8211;300 mg oral-loading dose of aspirin (non-enteric coated). If oral administration is not feasible, 75&#8211;250 mg can be given intravenously [<xref rid="B4-jcm-14-06241" ref-type="bibr">4</xref>]. Patient comfort should also be addressed, including oxygen therapy if saturations fall below 90% [<xref rid="B20-jcm-14-06241" ref-type="bibr">20</xref>], along with anti-emetics, nitrates, and appropriate analgesia, as shown in <xref rid="jcm-14-06241-f003" ref-type="fig">Figure 3</xref> [<xref rid="B4-jcm-14-06241" ref-type="bibr">4</xref>,<xref rid="B6-jcm-14-06241" ref-type="bibr">6</xref>].</p><p>Hofmann et al. demonstrated that routine oxygen supplementation in non-hypoxaemic patients with suspected MI (SpO<sub>2</sub> &#8805; 90%) offers no clinical benefit and is, therefore, not recommended [<xref rid="B21-jcm-14-06241" ref-type="bibr">21</xref>]. However, studies in canine models have shown a significant reduction in infarct size and improved left ventricular ejection fraction with oxygen therapy followed by reperfusion [<xref rid="B22-jcm-14-06241" ref-type="bibr">22</xref>]. These findings highlight the need for further research to assess the potential benefits of increased inspired oxygen concentrations in patients undergoing reperfusion therapy.</p><p>Intravenous access should be established promptly to enable effective pain management for severe chest pain, often requiring potent opioids. Diamorphine (2.5&#8211;5 mg) or morphine (5&#8211;10 mg) are commonly used due to their combined analgesic and anxiolytic effects [<xref rid="B4-jcm-14-06241" ref-type="bibr">4</xref>]. A multicentre randomised trial, by Charpentier et al., involving 684 patients found that nitrous oxide/oxygen with IV acetaminophen was less effective than morphine in controlling chest pain in patients with STEMI [<xref rid="B23-jcm-14-06241" ref-type="bibr">23</xref>]. However, opioids are associated with side effects such as nausea and vomiting, necessitating concurrent anti-emetics like cyclizine. Morphine has also been shown to delay activity of oral antiplatelet in STEMI patients by slowing gastrointestinal absorption [<xref rid="B24-jcm-14-06241" ref-type="bibr">24</xref>] and may increase the frequency of arterial hypoxaemia in the first 24 h post-MI [<xref rid="B25-jcm-14-06241" ref-type="bibr">25</xref>].</p><p>Sublingual nitrates alleviate ischaemic symptoms by reducing myocardial workload and oxygen demand through decreased preload and afterload [<xref rid="B26-jcm-14-06241" ref-type="bibr">26</xref>]. Though used for over a century, nitrates are contraindicated in certain situations, including hypotension, marked bradycardia or tachycardia, right ventricular infarction, severe aortic stenosis, and recent use of phosphodiesterase-5 inhibitors within the past 24&#8211;48 h [<xref rid="B5-jcm-14-06241" ref-type="bibr">5</xref>,<xref rid="B6-jcm-14-06241" ref-type="bibr">6</xref>].</p><p>Patients with ACS and acute or chronic anaemia should also be considered for blood transfusions, aiming for haemoglobin level of &#8805;10 g/dL [<xref rid="B27-jcm-14-06241" ref-type="bibr">27</xref>].</p></sec><sec id="sec4-jcm-14-06241"><title>4. Acute Management of STEMI</title><p>All patients with suspected STEMI should be offered a 300 mg loading dose of aspirin [<xref rid="B4-jcm-14-06241" ref-type="bibr">4</xref>], unless contraindicated&#8212;such as in cases of recent gastrointestinal bleeding, a history of severe hypersensitivity, or prior intracranial haemorrhage [<xref rid="B26-jcm-14-06241" ref-type="bibr">26</xref>]. Reperfusion eligibility should be assessed universally, without bias to age, sex, ethnicity, or level of consciousness.</p><p>For patients who are not candidates for immediate reperfusion therapy, medical management centres around dual antiplatelet therapy, typically ticagrelor in combination with aspirin. In individuals with a heightened bleeding risk, clopidogrel with aspirin or aspirin monotherapy may be considered. A cardiology review should follow, including evaluation of left ventricular function.</p><p>If the patient presents within 12 h of symptom onset and PCI is achievable within 120 min, primary PCI should be performed. PCI may still be appropriate beyond 12 h in the presence of ongoing ischaemia or cardiogenic shock. Prior to PCI, prasugrel in conjunction with aspirin is given, unless the patient is taking oral anticoagulants, in which case clopidogrel should be used instead [<xref rid="B4-jcm-14-06241" ref-type="bibr">4</xref>]. Radial access is generally favoured over femoral [<xref rid="B28-jcm-14-06241" ref-type="bibr">28</xref>,<xref rid="B29-jcm-14-06241" ref-type="bibr">29</xref>], with administration of unfractionated heparin with bailout glycoprotein inhibitors or bivalirudin [<xref rid="B30-jcm-14-06241" ref-type="bibr">30</xref>]. Drug-eluting stents are preferred in cases requiring stenting [<xref rid="B31-jcm-14-06241" ref-type="bibr">31</xref>]. For patients with multivessel disease in the absence of cardiogenic shock, the goal is complete revascularisation [<xref rid="B32-jcm-14-06241" ref-type="bibr">32</xref>]. Initial PCI should be of the culprit vessel, followed by PCI or CABG of significantly stenosed non-infarct-related vessels [<xref rid="B33-jcm-14-06241" ref-type="bibr">33</xref>]. The GUSTO-IIb trial demonstrated a significantly greater restoration of normal coronary flow with primary PCI compared to fibrinolysis [<xref rid="B34-jcm-14-06241" ref-type="bibr">34</xref>].</p><p>When PCI is not feasible within 120 min, fibrinolytic therapy should be promptly administered alongside an appropriate antithrombin. Robust randomised trials have shown that fibrinolysis can prevent approximately 30 early deaths per 1000 patients if given within 6 h of symptom onset [<xref rid="B35-jcm-14-06241" ref-type="bibr">35</xref>]. As with PCI, prasugrel and aspirin remain the first-line antiplatelet regimen with fibrinolysis unless contraindicated due to bleeding risk [<xref rid="B4-jcm-14-06241" ref-type="bibr">4</xref>].</p><p>An ECG should be repeated 60&#8211;90 min post-fibrinolysis to assess therapeutic response. Even if there is &#8805;50% resolution in ST-segment elevation along with relief of chest pain, angiography should be performed within 2&#8211;24 h [<xref rid="B36-jcm-14-06241" ref-type="bibr">36</xref>]. However, in cases of failed lysis, re-occlusion, or re-infarction, indicated by persistent or recurrent ST elevation, repeat fibrinolysis is discouraged. Instead, immediate angiography with follow-on PCI is indicated [<xref rid="B37-jcm-14-06241" ref-type="bibr">37</xref>], as outlined in <xref rid="jcm-14-06241-f004" ref-type="fig">Figure 4</xref>.</p><p>Irrespective of the initial strategy, all STEMI patients must be enrolled in a structured cardiac rehabilitation programme and receive comprehensive secondary prevention to optimise long-term outcomes [<xref rid="B32-jcm-14-06241" ref-type="bibr">32</xref>,<xref rid="B38-jcm-14-06241" ref-type="bibr">38</xref>].</p></sec><sec id="sec5-jcm-14-06241"><title>5. Acute Management of NSTEMI and Unstable Angina</title><p>As in STEMI, patients presenting with NSTEMI should be administered a 300 mg loading dose of aspirin, to be continued indefinitely unless contraindicated [<xref rid="B4-jcm-14-06241" ref-type="bibr">4</xref>]. Fondaparinux is the preferred initial antithrombin agent, unless there is a high bleeding risk or the patient requires immediate angiography [<xref rid="B39-jcm-14-06241" ref-type="bibr">39</xref>]. In patients with impaired renal function (creatinine &gt; 256 &#181;mol/L), unfractionated heparin should be considered, with dosage adjusted according to coagulation parameters [<xref rid="B40-jcm-14-06241" ref-type="bibr">40</xref>].</p><p>Risk stratification should be performed using the Global Registry of Acute Coronary Events (GRACE) score, incorporating clinical history, physical examination findings, ECG results, and key biochemical markers (troponin, creatinine, glucose, and haemoglobin). For patients with a predicted 6-month mortality of &#8804;3% (low risk), conservative management without angiography is appropriate. These patients should receive dual antiplatelet therapy with ticagrelor and aspirin, or clopidogrel and aspirin if there is an elevated bleeding risk. If clinical signs of ischaemia persist, angiography with follow-on PCI should be considered [<xref rid="B4-jcm-14-06241" ref-type="bibr">4</xref>,<xref rid="B32-jcm-14-06241" ref-type="bibr">32</xref>,<xref rid="B33-jcm-14-06241" ref-type="bibr">33</xref>].</p><p>Conversely, patients with a GRACE score &gt; 3% (intermediate to high risk) should undergo urgent angiography if they exhibit refractory angina or haemodynamic or electrical instability [<xref rid="B33-jcm-14-06241" ref-type="bibr">33</xref>]. If stable, angiography with or without PCI should be performed within 72 h, provided there are no contraindications such as active bleeding. These patients may be treated with prasugrel or ticagrelor alongside aspirin, with clopidogrel preferred for those on concurrent oral anticoagulation. The PCI protocol should follow established STEMI guidelines, including the use of unfractionated heparin and drug-eluting stents where indicated. This strategy of delayed PCI has been associated with improved in-hospital mortality and reduced length of stay in NSTEMI patients [<xref rid="B1-jcm-14-06241" ref-type="bibr">1</xref>]. Finally, all patients should undergo left ventricular function assessment and be referred for comprehensive cardiac rehabilitation and secondary prevention, as illustrated in <xref rid="jcm-14-06241-f005" ref-type="fig">Figure 5</xref> [<xref rid="B32-jcm-14-06241" ref-type="bibr">32</xref>,<xref rid="B41-jcm-14-06241" ref-type="bibr">41</xref>].</p></sec><sec id="sec6-jcm-14-06241"><title>6. Secondary Prevention</title><p>Following myocardial infarction, patients should be commenced on dual antiplatelet therapy (DAPT) for 12 months, after which lifelong aspirin at 75 mg is recommended, unless contraindicated. Ticagrelor or prasugrel with aspirin are offered as DAPT; however, clopidogrel should be used in individuals with active bleeding or a history of intracranial haemorrhage. In patients at elevated bleeding risk, DAPT may be shortened to 6 months, whereas those at high risk of recurrent cardiovascular events may benefit from extended therapy beyond 12 months [<xref rid="B4-jcm-14-06241" ref-type="bibr">4</xref>,<xref rid="B5-jcm-14-06241" ref-type="bibr">5</xref>,<xref rid="B6-jcm-14-06241" ref-type="bibr">6</xref>]. In-hospital bleeding reflects patient frailty in patients with ACS and should prompt careful monitoring during follow-up [<xref rid="B42-jcm-14-06241" ref-type="bibr">42</xref>]. For individuals at risk of gastrointestinal bleeding, a proton pump inhibitor (PPI) should be co-prescribed. As clopidogrel interacts with omeprazole, lansoprazole is the preferred alternative [<xref rid="B43-jcm-14-06241" ref-type="bibr">43</xref>].</p><p>Beta-blockers should be initiated within 24 h, provided there are no contraindications such as heart failure, hypotension, atrioventricular block, or reactive airway disease [<xref rid="B44-jcm-14-06241" ref-type="bibr">44</xref>]. Additionally, ACE inhibitors are recommended for those with left ventricular ejection fraction (LVEF) &lt; 40%, hypertension, diabetes, or chronic kidney disease. The EPHESUS trial demonstrated significant benefits of mineralocorticoid receptor antagonists in patients with heart failure or diabetes [<xref rid="B45-jcm-14-06241" ref-type="bibr">45</xref>].</p><p>A meta-analysis showed that sodium&#8211;glucose co-transporter 2 inhibitors (SGLT2is) significantly reduce major adverse cardiovascular events (MACEs) in diabetic patients [<xref rid="B46-jcm-14-06241" ref-type="bibr">46</xref>]. Post-MI, SGLT2i like empagliflozin have improved outcomes and lowered BNP levels in heart failure patients, as evidenced by the EMMY and DAPA-MI trials [<xref rid="B47-jcm-14-06241" ref-type="bibr">47</xref>,<xref rid="B48-jcm-14-06241" ref-type="bibr">48</xref>]. Recent evidence suggests that SGLT2i may also reduce infarct size [<xref rid="B49-jcm-14-06241" ref-type="bibr">49</xref>] and help prevent atrial fibrillation [<xref rid="B50-jcm-14-06241" ref-type="bibr">50</xref>], especially in patients without pre-existing heart failure.</p><p>High-intensity statins should be initiated promptly post-MI, irrespective of baseline lipid levels, to optimise long-term cardiovascular outcomes [<xref rid="B43-jcm-14-06241" ref-type="bibr">43</xref>,<xref rid="B51-jcm-14-06241" ref-type="bibr">51</xref>]. If patients are on maximal tolerated statin therapy, adding a non-statin medication (PCSK9 inhibitors or inclisiran) can further reduce risk of MACEs [<xref rid="B52-jcm-14-06241" ref-type="bibr">52</xref>]. Additionally, glucagon like peptide 1 receptor agonists have been shown in meta-analyses to lower MACE and cardiovascular mortality [<xref rid="B53-jcm-14-06241" ref-type="bibr">53</xref>]. The COLCOT and LoDoCo2 trials demonstrated that anti-inflammatory agents such as colchicine reduce MACE and cardiovascular deaths. However, there is a noted increase in non-cardiovascular mortality [<xref rid="B54-jcm-14-06241" ref-type="bibr">54</xref>,<xref rid="B55-jcm-14-06241" ref-type="bibr">55</xref>].</p><p>Beyond pharmacological management, comprehensive lifestyle interventions are essential. Smoking cessation counselling should be routinely offered, with evidence indicating a 50% reduction in recurrent myocardial infarction risk [<xref rid="B56-jcm-14-06241" ref-type="bibr">56</xref>]. Dietary modifications, particularly adherence to a Mediterranean style diet rich in fruits, vegetables, and oily fish, are advised to reduce total fat intake and encourage the substitution of saturated with polyunsaturated fats [<xref rid="B57-jcm-14-06241" ref-type="bibr">57</xref>]. Structured cardiac rehabilitation, including stress reduction strategies and regular cardiopulmonary exercise, should commence within 10 days post-discharge [<xref rid="B58-jcm-14-06241" ref-type="bibr">58</xref>,<xref rid="B59-jcm-14-06241" ref-type="bibr">59</xref>]. Additionally, meticulous control of contributory co-morbidities, such as hypertension and diabetes, is imperative to mitigate future cardiovascular events [<xref rid="B60-jcm-14-06241" ref-type="bibr">60</xref>].</p></sec><sec id="sec7-jcm-14-06241"><title>7. Post-MI Complications</title><p>A multitude of complications may ensue following MI, as illustrated in <xref rid="jcm-14-06241-f006" ref-type="fig">Figure 6</xref>. Sudden cardiac death remains a significant cause of mortality. This risk is attributed to a constellation of pathophysiological mechanisms including neurohormonal dysregulation, myocardial scar formation with impaired remodelling, autonomic imbalance, and evolving heart failure [<xref rid="B61-jcm-14-06241" ref-type="bibr">61</xref>]. Patients with ACS and reduced LVEF &lt; 40% have increased risk of life-threatening arrhythmias [<xref rid="B62-jcm-14-06241" ref-type="bibr">62</xref>]. Implantable cardioverter-defibrillators post-MI are therefore recommended for this cohort [<xref rid="B63-jcm-14-06241" ref-type="bibr">63</xref>].</p><p>Cardiac arrest is predominantly due to malignant arrhythmias such as ventricular fibrillation and can occur within the first 30 days post-MI. Resuscitated cardiac arrest patients with evidence of STEMI should be considered for transfer to a PCI centre [<xref rid="B64-jcm-14-06241" ref-type="bibr">64</xref>]. In contrast, immediate angiography is not recommended in post-arrest NSTEMI patients, as no clinical benefit has been demonstrated [<xref rid="B65-jcm-14-06241" ref-type="bibr">65</xref>].</p><p>Cardiogenic shock represents another critical complication, with 30-day mortality rates reaching approximately 30% and escalating to 50% within one year. The CULPRIT-SHOCK trial advocates for immediate coronary angiography and revascularisation of the infarct related artery in patients with MI associated cardiogenic shock, demonstrating an 8% reduction in 30-day mortality [<xref rid="B66-jcm-14-06241" ref-type="bibr">66</xref>]. Myocyte necrosis and the resultant loss of viable myocardium contribute to diminished ejection fraction and ventricular dysfunction. In refractory cardiogenic shock, mechanical circulatory support such as Impella or ECMO may be indicated to maintain cardiac output and end-organ perfusion while definitive therapy is instituted [<xref rid="B67-jcm-14-06241" ref-type="bibr">67</xref>].</p><p>Chronic heart failure may ensue due to sustained myocardial impairment. While loop diuretics can be utilised for symptomatic relief in cases of fluid overload, they offer no survival benefit. Long-term prognosis is significantly improved by the early introduction of ACE inhibitors and beta-blockers [<xref rid="B68-jcm-14-06241" ref-type="bibr">68</xref>].</p><p>Structural complications post-MI include the formation of left ventricular aneurysms and pseudoaneurysms, secondary to ischaemic damage and myocardial wall weakening. Pseudoaneurysms, which arise from contained myocardial rupture within pericardial adhesions, often manifest with signs of congestive heart failure, chest discomfort, and dyspnoea. These may be accompanied by sudden cardiac death. Electrocardiography may reveal persistent ST-segment elevation, while radiography often demonstrates cardiomegaly. Due to their association with thrombus formation and consequent stroke risk, anticoagulation is essential alongside consideration for percutaneous repair [<xref rid="B69-jcm-14-06241" ref-type="bibr">69</xref>].</p><p>Acute mitral regurgitation secondary to papillary muscle rupture, though less common in the modern era, remains associated with high mortality. It typically presents with acute pulmonary oedema progressing to cardiogenic shock. An early to mid-systolic murmur may be auscultated. Risk factors include advanced age, female sex, prior heart failure, and chronic kidney disease. Initial management may require vasoactive agents and mechanical ventilation, with urgent surgical assessment to determine the need for mitral valve replacement or concurrent coronary artery bypass grafting [<xref rid="B70-jcm-14-06241" ref-type="bibr">70</xref>,<xref rid="B71-jcm-14-06241" ref-type="bibr">71</xref>].</p><p>Left ventricular free wall rupture is considered the most common mechanical complication post-MI. Its precise incidence remains uncertain, largely due to its association with out of hospital sudden cardiac death, typically occurring within 1&#8211;2 weeks of the infarction [<xref rid="B72-jcm-14-06241" ref-type="bibr">72</xref>]. Delayed reperfusion has been identified as a significant risk factor [<xref rid="B73-jcm-14-06241" ref-type="bibr">73</xref>]. Clinical features often include pulsus paradoxus, raised jugular venous pressure, muffled heart sounds, and signs of tamponade physiology. Emergency management entails immediate pericardiocentesis followed by definitive surgical repair [<xref rid="B74-jcm-14-06241" ref-type="bibr">74</xref>].</p><p>Ventricular septal defects (VSDs) are another post-infarction mechanical complication. Usually arising within the first week, they can present variably from a pansystolic murmur to frank cardiogenic shock due to left to right shunting. Clinical signs include dyspnoea, hypotension, and cool extremities. Transthoracic echocardiography remains the diagnostic modality of choice to assess the size and direction of shunt. Without prompt surgical intervention, VSDs are associated with exceptionally high mortality [<xref rid="B72-jcm-14-06241" ref-type="bibr">72</xref>,<xref rid="B75-jcm-14-06241" ref-type="bibr">75</xref>].</p><p>Pericarditis post-MI may be classified as early (within 48 h) or late, with the latter often referred to as Dressler&#8217;s syndrome [<xref rid="B76-jcm-14-06241" ref-type="bibr">76</xref>,<xref rid="B77-jcm-14-06241" ref-type="bibr">77</xref>]. Early pericarditis typically presents with pleuritic chest pain exacerbated by lying supine, a pericardial friction rub on auscultation, and pericardial effusion on echocardiography. Dressler&#8217;s syndrome, occurring 2&#8211;6 weeks post-MI, is an immune-mediated phenomenon characterised by fever, elevated ESR, and pericardial effusion [<xref rid="B78-jcm-14-06241" ref-type="bibr">78</xref>]. Management involves NSAIDs with a PPI and colchicine to prevent recurrence. For patients already on antiplatelets, high-dose aspirin may be used for 2&#8211;4 weeks with gradual tapering. In cases where NSAIDs or aspirin are contraindicated, glucocorticoids can be administered [<xref rid="B79-jcm-14-06241" ref-type="bibr">79</xref>].</p></sec><sec sec-type="discussion" id="sec8-jcm-14-06241"><title>8. Discussion</title><p>Over the past century, the field of interventional cardiology has undergone transformative advancements, with procedures such as PCI, transcatheter aortic valve implantation, and left atrial appendage closure markedly improving patient outcomes in the management of cardiovascular disease [<xref rid="B80-jcm-14-06241" ref-type="bibr">80</xref>]. In parallel, the introduction and widespread adoption of potent antithrombotic agents and statins have significantly contributed to reducing low-density lipoprotein levels, thereby lowering the incidence of major vascular events, including myocardial infarction [<xref rid="B81-jcm-14-06241" ref-type="bibr">81</xref>]. The emergence of the cholesterol efflux and inflammatory hypothesis has further broadened the therapeutic landscape, providing new molecular targets aimed at modulating atherosclerotic progression and enhancing patient prognosis [<xref rid="B82-jcm-14-06241" ref-type="bibr">82</xref>]. Nonetheless, persistent challenges remain. A study by Jernberg et al. demonstrated that despite declining mortality rates, the risk of recurrent ischaemic cardiovascular events within the first year following myocardial infarction remains substantially high [<xref rid="B83-jcm-14-06241" ref-type="bibr">83</xref>].</p><p>Further research is warranted to innovate novel technologies that facilitate earlier detection of acute cardiac events. The integration of artificial intelligence holds considerable promise in augmenting existing diagnostic modalities and enhancing prognostic accuracy. AI-driven tools could be used to enhance ECG interpretation, detecting subtle ST-segment changes and early patterns of ischaemia. Incorporating AI into routine practice has the potential to increase diagnostic accuracy and risk stratification, accelerate decision making, and tailor management strategies for patients with ACS [<xref rid="B84-jcm-14-06241" ref-type="bibr">84</xref>].</p><p>In conclusion, the management of MI necessitates a prompt, comprehensive, and multidisciplinary approach. Timely and accurate diagnosis, primarily through ECG and troponin evaluation, enables differentiation between STEMI and NSTEMI to avoid delay in reperfusion. Robust secondary prevention remains paramount, encompassing lifelong antiplatelet therapy, structured lifestyle intervention, and rigorous optimisation of cardiovascular risk factors and comorbid conditions. Moreover, heightened clinical vigilance for post-infarction complications is essential, given their profound impact on long-term prognosis despite the substantial strides made in contemporary cardiovascular care. A patient-centred approach with shared decision making is essential to aligning with patient expectations and enhancing outcomes and overall experience.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>T.S.: drafting the manuscript, editing, and illustrations. H.S.-A.: conceptualisation, editing, and proofreading. Both authors contributed equally to this work. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-jcm-14-06241"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Mechanic</surname><given-names>O.J.</given-names></name><name name-style="western"><surname>Gavin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grossman</surname><given-names>S.A.</given-names></name></person-group><article-title>Acute Myocardial Infarction</article-title><source>StatPearls [Internet]</source><publisher-name>StatPearls Publishing</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2025</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK459269/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/books/NBK459269/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-08-24">(accessed on 24 August 2025)</date-in-citation></element-citation></ref><ref id="B2-jcm-14-06241"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bergmark</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Mathenge</surname><given-names>N.</given-names></name><name name-style="western"><surname>Merlini</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Lawrence-Wright</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Giugliano</surname><given-names>R.P.</given-names></name></person-group><article-title>Acute coronary syndromes</article-title><source>Lancet</source><year>2022</year><volume>399</volume><fpage>1347</fpage><lpage>1358</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)02391-6</pub-id><pub-id pub-id-type="pmid">35367005</pub-id><pub-id pub-id-type="pmcid">PMC8970581</pub-id></element-citation></ref><ref id="B3-jcm-14-06241"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsao</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Aday</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Almarzooq</surname><given-names>Z.I.</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>A.</given-names></name><name name-style="western"><surname>Beaton</surname><given-names>A.Z.</given-names></name><name name-style="western"><surname>Bittencourt</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Boehme</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Buxton</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Carson</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Commodore-Mensah</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Heart Disease and Stroke Statistics&#8212;2022 Update: A report from the American Heart Association</article-title><source>Circulation</source><year>2022</year><volume>145</volume><fpage>e153</fpage><lpage>e639</lpage><pub-id pub-id-type="doi">10.1161/CIR.0000000000001052</pub-id><pub-id pub-id-type="pmid">35078371</pub-id></element-citation></ref><ref id="B4-jcm-14-06241"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Byrne</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Rossello</surname><given-names>X.</given-names></name><name name-style="western"><surname>Coughlan</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Barbato</surname><given-names>E.</given-names></name><name name-style="western"><surname>Berry</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chieffo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Claeys</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Dan</surname><given-names>G.-A.</given-names></name><name name-style="western"><surname>Dweck</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Galbraith</surname><given-names>M.</given-names></name><etal/></person-group><article-title>2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC)</article-title><source>Eur. Heart J.</source><year>2023</year><volume>44</volume><fpage>3720</fpage><lpage>3826</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehad191</pub-id><pub-id pub-id-type="pmid">37622654</pub-id></element-citation></ref><ref id="B5-jcm-14-06241"><label>5.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Museedi</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Grossman</surname><given-names>S.A.</given-names></name></person-group><article-title>Acute Coronary Syndrome</article-title><source>StatPearls</source><publisher-name>StatPearls Publishing</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2025</year><pub-id pub-id-type="pmid">29083796</pub-id></element-citation></ref><ref id="B6-jcm-14-06241"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ibanez</surname><given-names>B.</given-names></name><name name-style="western"><surname>James</surname><given-names>S.</given-names></name><name name-style="western"><surname>Agewall</surname><given-names>S.</given-names></name><name name-style="western"><surname>Antunes</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Bucciarelli-Ducci</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bueno</surname><given-names>H.</given-names></name><name name-style="western"><surname>Caforio</surname><given-names>A.L.P.</given-names></name><name name-style="western"><surname>Crea</surname><given-names>F.</given-names></name><name name-style="western"><surname>Goudevenos</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Halvorsen</surname><given-names>S.</given-names></name><etal/></person-group><article-title>2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation</article-title><source>Eur. Heart J.</source><year>2018</year><volume>39</volume><fpage>119</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehx393</pub-id><pub-id pub-id-type="pmid">29198432</pub-id></element-citation></ref><ref id="B7-jcm-14-06241"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diercks</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Peacock</surname><given-names>W.F.</given-names></name><name name-style="western"><surname>Hiestand</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>A.Y.</given-names></name><name name-style="western"><surname>Pollack</surname><given-names>C.V.</given-names></name><name name-style="western"><surname>Kirk</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Gibler</surname><given-names>W.B.</given-names></name><name name-style="western"><surname>Ohman</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Blomkalns</surname><given-names>A.L.</given-names></name><etal/></person-group><article-title>Frequency and consequences of recording an electrocardiogram &gt; 10 minutes after arrival in an emergency room in non-ST-segment elevation acute coronary syndromes (from the CRUSADE Initiative)</article-title><source>Am. J. Cardiol.</source><year>2006</year><volume>97</volume><fpage>437</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2005.09.073</pub-id><pub-id pub-id-type="pmid">16461033</pub-id></element-citation></ref><ref id="B8-jcm-14-06241"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le May</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>So</surname><given-names>D.Y.</given-names></name><name name-style="western"><surname>Glover</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Froeschl</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maloney</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dionne</surname><given-names>R.</given-names></name><name name-style="western"><surname>Marquis</surname><given-names>J.-F.</given-names></name><name name-style="western"><surname>O&#8217;BRien</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Dick</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Reduction in mortality as a result of direct transport from the field to a receiving center for primary percutaneous coronary intervention</article-title><source>J. Am. Coll. Cardiol.</source><year>2012</year><volume>60</volume><fpage>1223</fpage><lpage>1230</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2012.07.008</pub-id><pub-id pub-id-type="pmid">23017532</pub-id></element-citation></ref><ref id="B9-jcm-14-06241"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rokos</surname><given-names>I.C.</given-names></name><name name-style="western"><surname>French</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Koenig</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Stratton</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Nighswonger</surname><given-names>B.</given-names></name><name name-style="western"><surname>Strunk</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jewell</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mahmud</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dunford</surname><given-names>J.V.</given-names></name><name name-style="western"><surname>Hokanson</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Integration of pre-hospital electrocardiograms and ST-elevation myocardial infarction receiving center (SRC) networks: Impact on door-to-balloon times across 10 independent regions</article-title><source>JACC Cardiovasc. Interv.</source><year>2009</year><volume>2</volume><fpage>339</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1016/j.jcin.2008.11.013</pub-id><pub-id pub-id-type="pmid">19463447</pub-id></element-citation></ref><ref id="B10-jcm-14-06241"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hochman</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Sleeper</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Webb</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Sanborn</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>White</surname><given-names>H.D.</given-names></name><name name-style="western"><surname>Talley</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Buller</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Slater</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Col</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Early revascularization in acute myocardial infarction complicated by cardiogenic shock</article-title><source>N. Engl. J. Med.</source><year>1999</year><volume>341</volume><fpage>625</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1056/NEJM199908263410901</pub-id><pub-id pub-id-type="pmid">10460813</pub-id></element-citation></ref><ref id="B11-jcm-14-06241"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopez-Sendon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Coma-Canella</surname><given-names>I.</given-names></name><name name-style="western"><surname>Alcasena</surname><given-names>S.</given-names></name><name name-style="western"><surname>Seoane</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gamallo</surname><given-names>C.</given-names></name></person-group><article-title>Electrocardiographic findings in acute right ventricular infarction: Sensitivity and specificity of electrocardiographic alterations in right precordial leads V4R, V3R, V1, V2, and V3</article-title><source>J. Am. Coll. Cardiol.</source><year>1985</year><volume>6</volume><fpage>1273</fpage><lpage>1279</lpage><pub-id pub-id-type="doi">10.1016/S0735-1097(85)80213-8</pub-id><pub-id pub-id-type="pmid">4067105</pub-id></element-citation></ref><ref id="B12-jcm-14-06241"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alaour</surname><given-names>B.</given-names></name><name name-style="western"><surname>Liew</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kaier</surname><given-names>T.E.</given-names></name></person-group><article-title>Cardiac Troponin-diagnostic problems and impact on cardiovascular disease</article-title><source>Ann. Med.</source><year>2018</year><volume>50</volume><fpage>655</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1080/07853890.2018.1530450</pub-id><pub-id pub-id-type="pmid">30265127</pub-id></element-citation></ref><ref id="B13-jcm-14-06241"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lipinski</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Esc&#225;rcega</surname><given-names>R.O.</given-names></name><name name-style="western"><surname>Torguson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Aldous</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Christ</surname><given-names>M.</given-names></name><name name-style="western"><surname>Collinson</surname><given-names>P.O.</given-names></name><name name-style="western"><surname>Goodacre</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Mair</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Comparison of conventional and high-sensitivity troponin in patients with chest pain: A collaborative meta-analysis</article-title><source>Am. Heart J.</source><year>2015</year><volume>169</volume><fpage>6</fpage><lpage>16.e6</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2014.10.007</pub-id><pub-id pub-id-type="pmid">25497242</pub-id></element-citation></ref><ref id="B14-jcm-14-06241"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Badertscher</surname><given-names>P.</given-names></name><name name-style="western"><surname>Boeddinghaus</surname><given-names>J.</given-names></name><name name-style="western"><surname>Twerenbold</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nestelberger</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wildi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wussler</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Puelacher</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gim&#233;nez</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Kozhuharov</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Direct comparison of the 0/1 h and 0/3 h algorithms for early rule-out of acute myocardial infarction</article-title><source>Circulation</source><year>2018</year><volume>137</volume><fpage>2536</fpage><lpage>2538</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.118.034260</pub-id><pub-id pub-id-type="pmid">29866778</pub-id></element-citation></ref><ref id="B15-jcm-14-06241"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neumann</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>S&#246;rensen</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>R&#252;bsamen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ojeda</surname><given-names>F.</given-names></name><name name-style="western"><surname>Schock</surname><given-names>A.</given-names></name><name name-style="western"><surname>Seddighizadeh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zeller</surname><given-names>T.</given-names></name><name name-style="western"><surname>Westermann</surname><given-names>D.</given-names></name><name name-style="western"><surname>Blankenberg</surname><given-names>S.</given-names></name></person-group><article-title>Evaluation of a new ultra-sensitivity troponin I assay in patients with suspected myocardial infarction</article-title><source>Int. J. Cardiol.</source><year>2019</year><volume>283</volume><fpage>35</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2018.12.001</pub-id><pub-id pub-id-type="pmid">30528623</pub-id></element-citation></ref><ref id="B16-jcm-14-06241"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chew</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Lambrakis</surname><given-names>K.</given-names></name><name name-style="western"><surname>Blyth</surname><given-names>A.</given-names></name><name name-style="western"><surname>Seshadri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Edmonds</surname><given-names>M.J.R.</given-names></name><name name-style="western"><surname>Briffa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cullen</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>S.</given-names></name><name name-style="western"><surname>Karnon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chuang</surname><given-names>A.</given-names></name><etal/></person-group><article-title>A randomized trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: The RAPID-TnT study</article-title><source>Circulation</source><year>2019</year><volume>140</volume><fpage>1543</fpage><lpage>1556</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.119.042891</pub-id><pub-id pub-id-type="pmid">31478763</pub-id></element-citation></ref><ref id="B17-jcm-14-06241"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neumann</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>S&#246;rensen</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>R&#252;bsamen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ojeda</surname><given-names>F.</given-names></name><name name-style="western"><surname>Renn&#233;</surname><given-names>T.</given-names></name><name name-style="western"><surname>Qaderi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Teltrop</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Quantius</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zeller</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Discrimination of patients with type 2 myocardial infarction</article-title><source>Eur. Heart J.</source><year>2017</year><volume>38</volume><fpage>3514</fpage><lpage>3520</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehx457</pub-id><pub-id pub-id-type="pmid">29020401</pub-id></element-citation></ref><ref id="B18-jcm-14-06241"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thygesen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Alpert</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Jaffe</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Chaitman</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Bax</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Morrow</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>White</surname><given-names>H.D.</given-names></name><collab>Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF)</collab></person-group><article-title>Fourth Universal Definition of Myocardial Infarction</article-title><source>Circulation</source><year>2018</year><volume>138</volume><fpage>e618</fpage><lpage>e651</lpage><pub-id pub-id-type="doi">10.1161/CIR.0000000000000617</pub-id><pub-id pub-id-type="pmid">30571511</pub-id></element-citation></ref><ref id="B19-jcm-14-06241"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Armillotta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bergamaschi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Paolisso</surname><given-names>P.</given-names></name><name name-style="western"><surname>Belmonte</surname><given-names>M.</given-names></name><name name-style="western"><surname>Angeli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sansonetti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stefanizzi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bertolini</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bodega</surname><given-names>F.</given-names></name><name name-style="western"><surname>Amicone</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Prognostic Relevance of Type 4a Myocardial Infarction and Periprocedural Myocardial Injury in Patients with Non-ST-Segment-Elevation Myocardial Infarction</article-title><source>Circulation</source><year>2025</year><volume>151</volume><fpage>760</fpage><lpage>772</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.124.070729</pub-id><pub-id pub-id-type="pmid">39968630</pub-id><pub-id pub-id-type="pmcid">PMC11913249</pub-id></element-citation></ref><ref id="B20-jcm-14-06241"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sukumalchantra</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Danzig</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rubins</surname><given-names>S.</given-names></name><name name-style="western"><surname>Alpern</surname><given-names>H.</given-names></name><name name-style="western"><surname>Swan</surname><given-names>H.J.</given-names></name></person-group><article-title>Correcting arterial hypoxemia by oxygen therapy in patients with acute myocardial infarction</article-title><source>Am. J. Cardiol.</source><year>1969</year><volume>24</volume><fpage>838</fpage><lpage>852</lpage><pub-id pub-id-type="doi">10.1016/0002-9149(69)90474-3</pub-id><pub-id pub-id-type="pmid">5360238</pub-id></element-citation></ref><ref id="B21-jcm-14-06241"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hofmann</surname><given-names>R.</given-names></name><name name-style="western"><surname>James</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Jernberg</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lindahl</surname><given-names>B.</given-names></name><name name-style="western"><surname>Erlinge</surname><given-names>D.</given-names></name><name name-style="western"><surname>Witt</surname><given-names>N.</given-names></name><name name-style="western"><surname>Arefalk</surname><given-names>G.</given-names></name><name name-style="western"><surname>Frick</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alfredsson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nilsson</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Oxygen therapy in suspected acute myocardial infarction</article-title><source>N. Engl. J. Med.</source><year>2017</year><volume>377</volume><fpage>1240</fpage><lpage>1249</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1706222</pub-id><pub-id pub-id-type="pmid">28844200</pub-id></element-citation></ref><ref id="B22-jcm-14-06241"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelly</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Hursy</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Parillo</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Schaer</surname><given-names>G.L.</given-names></name></person-group><article-title>Effect of 100% oxygen administration on infarct size and left ventricular dysfunction in a canine model of myocardial infarction and reperfusion</article-title><source>Am. Heart J.</source><year>1995</year><volume>130</volume><fpage>957</fpage><lpage>965</lpage><pub-id pub-id-type="doi">10.1016/0002-8703(95)90194-9</pub-id><pub-id pub-id-type="pmid">7484756</pub-id></element-citation></ref><ref id="B23-jcm-14-06241"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charpentier</surname><given-names>S.</given-names></name><name name-style="western"><surname>Galinski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bounes</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ricard-Hibon</surname><given-names>A.</given-names></name><name name-style="western"><surname>El-Khoury</surname><given-names>C.</given-names></name><name name-style="western"><surname>Elbaz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ageron</surname><given-names>F.-X.</given-names></name><name name-style="western"><surname>Manzo-Silberman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Soulat</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lapostolle</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Nitrous oxide/oxygen plus acetaminophen versus morphine in ST elevation myocardial infarction: Open-label, cluster-randomized, non-inferiority study</article-title><source>Scand. J. Trauma Resusc. Emerg. Med.</source><year>2020</year><volume>28</volume><fpage>36</fpage><pub-id pub-id-type="doi">10.1186/s13049-020-00731-y</pub-id><pub-id pub-id-type="pmid">32398160</pub-id><pub-id pub-id-type="pmcid">PMC7218609</pub-id></element-citation></ref><ref id="B24-jcm-14-06241"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parodi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bellandi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Xanthopoulou</surname><given-names>I.</given-names></name><name name-style="western"><surname>Capranzano</surname><given-names>P.</given-names></name><name name-style="western"><surname>Capodanno</surname><given-names>D.</given-names></name><name name-style="western"><surname>Valenti</surname><given-names>R.</given-names></name><name name-style="western"><surname>Stavrou</surname><given-names>K.</given-names></name><name name-style="western"><surname>Migliorini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Antoniucci</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tamburino</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention</article-title><source>Circ. Cardiovasc. Interv.</source><year>2015</year><volume>8</volume><fpage>e001593</fpage><pub-id pub-id-type="doi">10.1161/CIRCINTERVENTIONS.114.001593</pub-id><pub-id pub-id-type="pmid">25552565</pub-id></element-citation></ref><ref id="B25-jcm-14-06241"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Channer</surname><given-names>K.S.</given-names></name></person-group><article-title>Hypoxaemia and supplemental oxygen therapy in the first 24 hours after myocardial infarction: The role of pulse oximetry</article-title><source>J. R. Coll. Physicians Lond.</source><year>1997</year><volume>31</volume><fpage>657</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1016/S0035-8819(25)00089-3</pub-id><pub-id pub-id-type="pmid">9409501</pub-id><pub-id pub-id-type="pmcid">PMC5421075</pub-id></element-citation></ref><ref id="B26-jcm-14-06241"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maxwell</surname><given-names>S.</given-names></name></person-group><article-title>Emergency management of acute myocardial infarction</article-title><source>Br. J. Clin. Pharmacol.</source><year>1999</year><volume>48</volume><fpage>284</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2125.1999.00998.x</pub-id><pub-id pub-id-type="pmid">10510138</pub-id><pub-id pub-id-type="pmcid">PMC2014343</pub-id></element-citation></ref><ref id="B27-jcm-14-06241"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carson</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>H&#233;bert</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Goodman</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Bertolet</surname><given-names>M.</given-names></name><name name-style="western"><surname>Glynn</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Chaitman</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Simon</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lopes</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Goldsweig</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>Restrictive or liberal transfusion strategy in myocardial infarction and anemia</article-title><source>N. Engl. J. Med.</source><year>2023</year><volume>389</volume><fpage>2446</fpage><lpage>2456</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2307983</pub-id><pub-id pub-id-type="pmid">37952133</pub-id><pub-id pub-id-type="pmcid">PMC10837004</pub-id></element-citation></ref><ref id="B28-jcm-14-06241"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valgimigli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gagnor</surname><given-names>A.</given-names></name><name name-style="western"><surname>Calabr&#243;</surname><given-names>P.</given-names></name><name name-style="western"><surname>Frigoli</surname><given-names>E.</given-names></name><name name-style="western"><surname>Leonardi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zaro</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rubartelli</surname><given-names>P.</given-names></name><name name-style="western"><surname>Briguori</surname><given-names>C.</given-names></name><name name-style="western"><surname>And&#242;</surname><given-names>G.</given-names></name><name name-style="western"><surname>Repetto</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: A randomised multicentre trial</article-title><source>Lancet</source><year>2015</year><volume>385</volume><fpage>2465</fpage><lpage>2476</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(15)60292-6</pub-id><pub-id pub-id-type="pmid">25791214</pub-id></element-citation></ref><ref id="B29-jcm-14-06241"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kok</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Weernink</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>von Birgelen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fens</surname><given-names>A.</given-names></name><name name-style="western"><surname>van der Heijden</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>van Til</surname><given-names>J.A.</given-names></name></person-group><article-title>Patient preference for radial versus femoral vascular access for elective coronary procedures: The PREVAS study</article-title><source>Catheter. Cardiovasc. Interv.</source><year>2018</year><volume>91</volume><fpage>17</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1002/ccd.27039</pub-id><pub-id pub-id-type="pmid">28470994</pub-id><pub-id pub-id-type="pmcid">PMC5811812</pub-id></element-citation></ref><ref id="B30-jcm-14-06241"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomised trial</article-title><source>Lancet</source><year>2022</year><volume>400</volume><fpage>1847</fpage><lpage>1857</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(22)01999-7</pub-id><pub-id pub-id-type="pmid">36351459</pub-id></element-citation></ref><ref id="B31-jcm-14-06241"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>B&#248;naa</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Mannsverk</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wiseth</surname><given-names>R.</given-names></name><name name-style="western"><surname>Aaberge</surname><given-names>L.</given-names></name><name name-style="western"><surname>Myreng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nyg&#229;rd</surname><given-names>O.</given-names></name><name name-style="western"><surname>Nilsen</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Kl&#248;w</surname><given-names>N.-E.</given-names></name><name name-style="western"><surname>Uchto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Trovik</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Drug-eluting or bare-metal stents for coronary artery disease</article-title><source>N. Engl. J. Med.</source><year>2016</year><volume>375</volume><fpage>1242</fpage><lpage>1252</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1607991</pub-id><pub-id pub-id-type="pmid">27572953</pub-id></element-citation></ref><ref id="B32-jcm-14-06241"><label>32.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>National Institute for Health and Care Excellence</collab></person-group><article-title>Acute Coronary Syndromes, NICE Guideline NG185</article-title><year>2020</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nice.org.uk/guidance/ng185" ext-link-type="uri">https://www.nice.org.uk/guidance/ng185</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-04-14">(accessed on 14 April 2025)</date-in-citation></element-citation></ref><ref id="B33-jcm-14-06241"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rao</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>O&#8217;dOnoghue</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Ruel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rab</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tamis-Holland</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Baber</surname><given-names>U.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Cruz-Ruiz</surname><given-names>M.</given-names></name><etal/></person-group><article-title>2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients with Acute Coronary Syndromes</article-title><source>Circulation</source><year>2025</year><volume>151</volume><fpage>13</fpage><pub-id pub-id-type="doi">10.1161/CIR.0000000000001328</pub-id><pub-id pub-id-type="pmid">40163565</pub-id></element-citation></ref><ref id="B34-jcm-14-06241"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>The GUSTO-IIb Angioplasty Substudy Investigators</collab></person-group><article-title>A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction</article-title><source>N. Engl. J. Med.</source><year>1997</year><volume>336</volume><fpage>1621</fpage><lpage>1628</lpage><pub-id pub-id-type="doi">10.1056/NEJM199706053362301</pub-id><pub-id pub-id-type="pmid">9173270</pub-id></element-citation></ref><ref id="B35-jcm-14-06241"><label>35.</label><element-citation publication-type="journal"><article-title>Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients</article-title><source>Lancet</source><year>1994</year><volume>343</volume><fpage>311</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(94)91161-4</pub-id><pub-id pub-id-type="pmid">7905143</pub-id></element-citation></ref><ref id="B36-jcm-14-06241"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fernandez-Avil&#233;s</surname><given-names>F.</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Castro-Beiras</surname><given-names>A.</given-names></name><name name-style="western"><surname>V&#225;zquez</surname><given-names>N.</given-names></name><name name-style="western"><surname>Blanco</surname><given-names>J.</given-names></name><name name-style="western"><surname>Alonso-Briales</surname><given-names>J.</given-names></name><name name-style="western"><surname>L&#243;pez-Mesa</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Vazquez</surname><given-names>F.</given-names></name><name name-style="western"><surname>Calvo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Elbal</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): A randomised controlled trial</article-title><source>Lancet</source><year>2004</year><volume>364</volume><fpage>1045</fpage><lpage>1053</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(04)17059-1</pub-id><pub-id pub-id-type="pmid">15380963</pub-id></element-citation></ref><ref id="B37-jcm-14-06241"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gershlick</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Stephens-Lloyd</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abrams</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Uren</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>de Belder</surname><given-names>A.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pitt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Banning</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction</article-title><source>N. Engl. J. Med.</source><year>2005</year><volume>353</volume><fpage>2758</fpage><lpage>2768</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa050849</pub-id><pub-id pub-id-type="pmid">16382062</pub-id></element-citation></ref><ref id="B38-jcm-14-06241"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abreu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Frederix</surname><given-names>I.</given-names></name><name name-style="western"><surname>Dendale</surname><given-names>P.</given-names></name><name name-style="western"><surname>Janssen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>P.</given-names></name><name name-style="western"><surname>Piepoli</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>V&#246;ller</surname><given-names>H.</given-names></name><name name-style="western"><surname>Davos</surname><given-names>C.H.</given-names></name><collab>the Secondary Prevention and Rehabilitation Section of EAPC Reviewers</collab></person-group><article-title>Standardization and quality improvement of secondary prevention through cardiovascular rehabilitation programmes in Europe: The avenue towards EAPC accreditation programme: A position statement</article-title><source>Eur. J. Prev. Cardiol.</source><year>2020</year><volume>28</volume><fpage>496</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1177/2047487320924912</pub-id><pub-id pub-id-type="pmid">33611459</pub-id></element-citation></ref><ref id="B39-jcm-14-06241"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yusuf</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Chrolavicius</surname><given-names>S.</given-names></name><name name-style="western"><surname>Afzal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pogue</surname><given-names>J.</given-names></name><name name-style="western"><surname>Granger</surname><given-names>C.B.</given-names></name></person-group><article-title>Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators Comparison of fondaparinux enoxaparin in acute coronary syndromes</article-title><source>N. Engl. J. Med.</source><year>2006</year><volume>354</volume><fpage>1464</fpage><lpage>1476</lpage><pub-id pub-id-type="pmid">16537663</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa055443</pub-id></element-citation></ref><ref id="B40-jcm-14-06241"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haider</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>M.U.</given-names></name><name name-style="western"><surname>Kassianides</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hazara</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>N.</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>D.N.</given-names></name></person-group><article-title>Diagnosis and management of ACS in patients with ESRD on haemodialysis: A comprehensive review</article-title><source>Br. J. Cardiol.</source><year>2025</year><volume>32</volume><fpage>7</fpage><lpage>11</lpage></element-citation></ref><ref id="B41-jcm-14-06241"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ambrosetti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Abreu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Corr&#224;</surname><given-names>U.</given-names></name><name name-style="western"><surname>Davos</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Frederix</surname><given-names>I.</given-names></name><name name-style="western"><surname>Iliou</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Pedretti</surname><given-names>R.F.E.</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>J.-P.</given-names></name><name name-style="western"><surname>Vigorito</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation</article-title><source>Eur. J. Prev. Cardiol.</source><year>2020</year><volume>28</volume><fpage>460</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1177/2047487320913379</pub-id><pub-id pub-id-type="pmid">33611446</pub-id></element-citation></ref><ref id="B42-jcm-14-06241"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spadafora</surname><given-names>L.</given-names></name><name name-style="western"><surname>Betti</surname><given-names>M.</given-names></name><name name-style="western"><surname>D&#8217;AScenzo</surname><given-names>F.</given-names></name><name name-style="western"><surname>De Ferrari</surname><given-names>G.</given-names></name><name name-style="western"><surname>De Filippo</surname><given-names>O.</given-names></name><name name-style="western"><surname>Gaudio</surname><given-names>C.</given-names></name><name name-style="western"><surname>Collet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sabouret</surname><given-names>P.</given-names></name><name name-style="western"><surname>Agostoni</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zivelonghi</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Impact of in-hospital bleeding on post-discharge therapies and prognosis in acute coronary syndromes</article-title><source>J. Cardiovasc. Pharmacol.</source><year>2025</year><volume>85</volume><fpage>322</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1097/FJC.0000000000001678</pub-id><pub-id pub-id-type="pmid">39928732</pub-id></element-citation></ref><ref id="B43-jcm-14-06241"><label>43.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>National Institute for Health and Care Excellence</collab></person-group><source>Myocardial Infarction: Cardiac Rehabilitation and Prevention of Further Cardiovascular Disease CG172</source><publisher-name>National Institute for Health and Care Excellence</publisher-name><publisher-loc>London, UK</publisher-loc><year>2013</year><pub-id pub-id-type="pmid">31891465</pub-id></element-citation></ref><ref id="B44-jcm-14-06241"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freemantle</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cleland</surname><given-names>J.</given-names></name><name name-style="western"><surname>Young</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mason</surname><given-names>J.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>J.</given-names></name></person-group><article-title>Beta blockade after myocardial infarction: Systematic review and meta regression analysis</article-title><source>BMJ</source><year>1999</year><volume>318</volume><fpage>1730</fpage><lpage>1737</lpage><pub-id pub-id-type="doi">10.1136/bmj.318.7200.1730</pub-id><pub-id pub-id-type="pmid">10381708</pub-id><pub-id pub-id-type="pmcid">PMC31101</pub-id></element-citation></ref><ref id="B45-jcm-14-06241"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pitt</surname><given-names>B.</given-names></name><name name-style="western"><surname>Remme</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zannad</surname><given-names>F.</given-names></name><name name-style="western"><surname>Neaton</surname><given-names>J.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>F.</given-names></name><name name-style="western"><surname>Roniker</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bittman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hurley</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kleiman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gatlin</surname><given-names>M.</given-names></name></person-group><article-title>Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction</article-title><source>N. Engl. J. Med.</source><year>2003</year><volume>348</volume><fpage>1309</fpage><lpage>1321</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa030207</pub-id><pub-id pub-id-type="pmid">12668699</pub-id></element-citation></ref><ref id="B46-jcm-14-06241"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zelniker</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Wiviott</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Raz</surname><given-names>I.</given-names></name><name name-style="western"><surname>Im</surname><given-names>K.</given-names></name><name name-style="western"><surname>Goodrich</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bonaca</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Mosenzon</surname><given-names>O.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cahn</surname><given-names>A.</given-names></name><name name-style="western"><surname>Furtado</surname><given-names>R.H.M.</given-names></name><etal/></person-group><article-title>SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials</article-title><source>Lancet</source><year>2019</year><volume>393</volume><fpage>31</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)32590-X</pub-id><pub-id pub-id-type="pmid">30424892</pub-id></element-citation></ref><ref id="B47-jcm-14-06241"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>von Lewinski</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kolesnik</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tripolt</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Pferschy</surname><given-names>P.N.</given-names></name><name name-style="western"><surname>Benedikt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wallner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alber</surname><given-names>H.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lichtenauer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Saely</surname><given-names>C.H.</given-names></name><etal/></person-group><article-title>Empagliflozin in acute myocardial infarction: The EMMY trial</article-title><source>Eur. Heart J.</source><year>2022</year><volume>43</volume><fpage>4421</fpage><lpage>4432</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehac494</pub-id><pub-id pub-id-type="pmid">36036746</pub-id><pub-id pub-id-type="pmcid">PMC9622301</pub-id></element-citation></ref><ref id="B48-jcm-14-06241"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>James</surname><given-names>S.</given-names></name><name name-style="western"><surname>Erlinge</surname><given-names>D.</given-names></name><name name-style="western"><surname>Storey</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>McGuire</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>de Belder</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eriksson</surname><given-names>N.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Austin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Arefalk</surname><given-names>G.</given-names></name><name name-style="western"><surname>Carrick</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Dapagliflozin in myocardial infarction without diabetes or heart failure</article-title><source>N. Engl. J. Med. Evid.</source><year>2024</year><volume>3</volume><fpage>2</fpage><pub-id pub-id-type="doi">10.1056/EVIDoa2300286</pub-id><pub-id pub-id-type="pmid">38320489</pub-id></element-citation></ref><ref id="B49-jcm-14-06241"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Armillotta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Angeli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Paolisso</surname><given-names>P.</given-names></name><name name-style="western"><surname>Belmonte</surname><given-names>M.</given-names></name><name name-style="western"><surname>Raschi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Di Dalmazi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Amicone</surname><given-names>S.</given-names></name><name name-style="western"><surname>Canton</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fedele</surname><given-names>D.</given-names></name><name name-style="western"><surname>Suma</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure</article-title><source>Pharmacol. Ther.</source><year>2025</year><volume>270</volume><fpage>108861</fpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2025.108861</pub-id><pub-id pub-id-type="pmid">40245989</pub-id></element-citation></ref><ref id="B50-jcm-14-06241"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fedele</surname><given-names>D.</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Maida</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vasumini</surname><given-names>N.</given-names></name><name name-style="western"><surname>Amicone</surname><given-names>S.</given-names></name><name name-style="western"><surname>Canton</surname><given-names>L.</given-names></name><name name-style="western"><surname>Di Leo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Basile</surname><given-names>M.</given-names></name><name name-style="western"><surname>Manaresi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Angeli</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Prevention of atrial fibrillation with SGLT2 inhibitors across the spectrum of cardiovascular disorders: A meta-analysis of randomized controlled trials</article-title><source>Eur. Heart J. Cardiovasc. Pharmacother.</source><year>2025</year><volume>11</volume><fpage>441</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1093/ehjcvp/pvaf040</pub-id><pub-id pub-id-type="pmid">40464647</pub-id><pub-id pub-id-type="pmcid">PMC12342982</pub-id></element-citation></ref><ref id="B51-jcm-14-06241"><label>51.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Basit</surname><given-names>H.</given-names></name><name name-style="western"><surname>Malik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Huecker</surname><given-names>M.R.</given-names></name></person-group><article-title>Non-ST-Segment Elevation Myocardial Infarction</article-title><source>StatPearls [Internet]</source><publisher-name>StatPearls Publishing</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2025</year><pub-id pub-id-type="pmid">30020600</pub-id></element-citation></ref><ref id="B52-jcm-14-06241"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cannon</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Blazing</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Giugliano</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>McCagg</surname><given-names>A.</given-names></name><name name-style="western"><surname>White</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Th&#233;roux</surname><given-names>P.</given-names></name><name name-style="western"><surname>Darius</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Ophuis</surname><given-names>T.O.</given-names></name><name name-style="western"><surname>Jukema</surname><given-names>J.W.</given-names></name><etal/></person-group><article-title>Ezetimibe added to statin therapy after acute coronary syndromes</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>372</volume><fpage>2387</fpage><lpage>2397</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1410489</pub-id><pub-id pub-id-type="pmid">26039521</pub-id></element-citation></ref><ref id="B53-jcm-14-06241"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kristensen</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>R&#248;rth</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jhund</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Docherty</surname><given-names>K.F.</given-names></name><name name-style="western"><surname>Sattar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Preiss</surname><given-names>D.</given-names></name><name name-style="western"><surname>K&#248;ber</surname><given-names>L.</given-names></name><name name-style="western"><surname>Petrie</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>McMurray</surname><given-names>J.J.V.</given-names></name></person-group><article-title>Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials</article-title><source>Lancet Diabetes Endocrinol.</source><year>2019</year><volume>7</volume><fpage>776</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1016/S2213-8587(19)30249-9</pub-id><pub-id pub-id-type="pmid">31422062</pub-id></element-citation></ref><ref id="B54-jcm-14-06241"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tardif</surname><given-names>J.-C.</given-names></name><name name-style="western"><surname>Kouz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Waters</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Bertrand</surname><given-names>O.F.</given-names></name><name name-style="western"><surname>Diaz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Maggioni</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gamra</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kiwan</surname><given-names>G.S.</given-names></name><etal/></person-group><article-title>Efficacy and safety of low-dose colchicine after myocardial infarction</article-title><source>N. Engl. J. Med.</source><year>2019</year><volume>381</volume><fpage>2497</fpage><lpage>2505</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1912388</pub-id><pub-id pub-id-type="pmid">31733140</pub-id></element-citation></ref><ref id="B55-jcm-14-06241"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nidorf</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Fiolet</surname><given-names>A.T.L.</given-names></name><name name-style="western"><surname>Mosterd</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eikelboom</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Schut</surname><given-names>A.</given-names></name><name name-style="western"><surname>Opstal</surname><given-names>T.S.J.</given-names></name><name name-style="western"><surname>The</surname><given-names>S.H.K.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.-F.</given-names></name><name name-style="western"><surname>Ireland</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Lenderink</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Colchicine in patients with chronic coronary disease</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>383</volume><fpage>1838</fpage><lpage>1847</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2021372</pub-id><pub-id pub-id-type="pmid">32865380</pub-id></element-citation></ref><ref id="B56-jcm-14-06241"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Critchley</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Capewell</surname><given-names>S.</given-names></name></person-group><article-title>Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: A systematic review</article-title><source>JAMA</source><year>2003</year><volume>290</volume><fpage>86</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1001/jama.290.1.86</pub-id><pub-id pub-id-type="pmid">12837716</pub-id></element-citation></ref><ref id="B57-jcm-14-06241"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delgado-Lista</surname><given-names>J.</given-names></name><name name-style="western"><surname>Alcala-Diaz</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Torres-Pe&#241;a</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Quintana-Navarro</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Fuentes</surname><given-names>F.</given-names></name><name name-style="western"><surname>Garcia-Rios</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ortiz-Morales</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Gonzalez-Requero</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Perez-Caballero</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Yubero-Serrano</surname><given-names>E.M.</given-names></name><etal/></person-group><article-title>Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): A randomised controlled trial</article-title><source>Lancet</source><year>2022</year><volume>399</volume><fpage>1876</fpage><lpage>1885</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(22)00122-2</pub-id><pub-id pub-id-type="pmid">35525255</pub-id></element-citation></ref><ref id="B58-jcm-14-06241"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dibben</surname><given-names>G.</given-names></name><name name-style="western"><surname>Faulkner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Oldridge</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rees</surname><given-names>K.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Zwisler</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>R.S.</given-names></name></person-group><article-title>Exercise-based cardiac rehabilitation for coronary heart disease</article-title><source>Cochrane Database Syst. Rev.</source><year>2021</year><volume>11</volume><fpage>CD001800</fpage><pub-id pub-id-type="pmid">34741536</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/14651858.CD001800.pub4</pub-id><pub-id pub-id-type="pmcid">PMC8571912</pub-id></element-citation></ref><ref id="B59-jcm-14-06241"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ekblom</surname><given-names>O.</given-names></name><name name-style="western"><surname>Ek</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cider</surname><given-names>&#197;.</given-names></name><name name-style="western"><surname>Hambraeus</surname><given-names>K.</given-names></name><name name-style="western"><surname>B&#246;rjesson</surname><given-names>M.</given-names></name></person-group><article-title>Increased physical activity post-myocardial infarction is related to reduced mortality: Results from the SWEDEHEART registry</article-title><source>J. Am. Heart Assoc.</source><year>2018</year><volume>7</volume><fpage>e010108</fpage><pub-id pub-id-type="doi">10.1161/JAHA.118.010108</pub-id><pub-id pub-id-type="pmid">30561263</pub-id><pub-id pub-id-type="pmcid">PMC6405601</pub-id></element-citation></ref><ref id="B60-jcm-14-06241"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Isted</surname><given-names>A.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>R.</given-names></name><name name-style="western"><surname>Oakeshott</surname><given-names>P.</given-names></name></person-group><article-title>Secondary prevention following myocardial infarction: A clinical update</article-title><source>Br. J. Gen. Pract.</source><year>2018</year><volume>68</volume><fpage>151</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.3399/bjgp18X695261</pub-id><pub-id pub-id-type="pmid">29472228</pub-id><pub-id pub-id-type="pmcid">PMC5819978</pub-id></element-citation></ref><ref id="B61-jcm-14-06241"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parkash</surname><given-names>R.</given-names></name><name name-style="western"><surname>MacIntyre</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dorian</surname><given-names>P.</given-names></name></person-group><article-title>Predicting sudden cardiac death after myocardial infarction: A great unsolved challenge</article-title><source>Circ. Arrhythm. Electrophysiol.</source><year>2021</year><volume>14</volume><fpage>e009422</fpage><pub-id pub-id-type="doi">10.1161/CIRCEP.120.009422</pub-id><pub-id pub-id-type="pmid">33464943</pub-id></element-citation></ref><ref id="B62-jcm-14-06241"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomsen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jacobsen</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Huikuri</surname><given-names>H.V.</given-names></name><name name-style="western"><surname>Thomsen</surname><given-names>P.E.B.</given-names></name><name name-style="western"><surname>Jons</surname><given-names>C.</given-names></name></person-group><article-title>Risk of arrhythmias after myocardial infarction in patients with left ventricular systolic dysfunction according to mode of revascularization: A CARISMA substudy</article-title><source>EP Europace</source><year>2021</year><volume>23</volume><fpage>616</fpage><lpage>623</lpage><pub-id pub-id-type="doi">10.1093/europace/euaa273</pub-id><pub-id pub-id-type="pmid">33200171</pub-id></element-citation></ref><ref id="B63-jcm-14-06241"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moss</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Zareba</surname><given-names>W.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wilber</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Cannom</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Daubert</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Higgins</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>M.L.</given-names></name></person-group><article-title>Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction</article-title><source>N. Engl. J. Med.</source><year>2002</year><volume>346</volume><fpage>877</fpage><lpage>883</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa013474</pub-id><pub-id pub-id-type="pmid">11907286</pub-id></element-citation></ref><ref id="B64-jcm-14-06241"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wnent</surname><given-names>J.</given-names></name><name name-style="western"><surname>Seewald</surname><given-names>S.</given-names></name><name name-style="western"><surname>Heringlake</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lemke</surname><given-names>H.</given-names></name><name name-style="western"><surname>Brauer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lefering</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jantzen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bein</surname><given-names>B.</given-names></name><name name-style="western"><surname>Messelken</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Choice of hospital after out-of-hospital cardiac arrest-a decision with far-reaching consequences: A study in a large German city</article-title><source>Crit. Care</source><year>2012</year><volume>16</volume><fpage>R164</fpage><pub-id pub-id-type="doi">10.1186/cc11516</pub-id><pub-id pub-id-type="pmid">22971320</pub-id><pub-id pub-id-type="pmcid">PMC3682259</pub-id></element-citation></ref><ref id="B65-jcm-14-06241"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desch</surname><given-names>S.</given-names></name><name name-style="western"><surname>Freund</surname><given-names>A.</given-names></name><name name-style="western"><surname>Akin</surname><given-names>I.</given-names></name><name name-style="western"><surname>Behnes</surname><given-names>M.</given-names></name><name name-style="western"><surname>Preusch</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Zelniker</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Skurk</surname><given-names>C.</given-names></name><name name-style="western"><surname>Landmesser</surname><given-names>U.</given-names></name><name name-style="western"><surname>Graf</surname><given-names>T.</given-names></name><name name-style="western"><surname>Eitel</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Angiography after out-of-hospital cardiac arrest without ST-segment elevation</article-title><source>N. Engl. J. Med.</source><year>2021</year><volume>385</volume><fpage>2544</fpage><lpage>2553</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2101909</pub-id><pub-id pub-id-type="pmid">34459570</pub-id></element-citation></ref><ref id="B66-jcm-14-06241"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thiele</surname><given-names>H.</given-names></name><name name-style="western"><surname>Akin</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sandri</surname><given-names>M.</given-names></name><name name-style="western"><surname>De Waha-Thiele</surname><given-names>S.</given-names></name><name name-style="western"><surname>Meyer-Saraei</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fuernau</surname><given-names>G.</given-names></name><name name-style="western"><surname>Eitel</surname><given-names>I.</given-names></name><name name-style="western"><surname>Nordbeck</surname><given-names>P.</given-names></name><name name-style="western"><surname>Geisler</surname><given-names>T.</given-names></name><name name-style="western"><surname>Landmesser</surname><given-names>U.</given-names></name><etal/></person-group><article-title>One-year outcomes after PCI strategies in cardiogenic shock</article-title><source>N. Engl. J. Med.</source><year>2018</year><volume>379</volume><fpage>1699</fpage><lpage>1710</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1808788</pub-id><pub-id pub-id-type="pmid">30145971</pub-id></element-citation></ref><ref id="B67-jcm-14-06241"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stub</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ball</surname><given-names>J.</given-names></name><name name-style="western"><surname>Burell</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ihle</surname><given-names>J.</given-names></name><name name-style="western"><surname>Theng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tsintzos</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kaye</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Seage</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mudge</surname><given-names>M.</given-names></name></person-group><article-title>Impella compared to venoarterial extracorporeal membrane oxygenation in cardiogenic shock: A systematic review and meta-analysis of propensity score matched studies</article-title><source>Shock</source><year>2025</year><volume>63</volume><fpage>512</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1097/SHK.0000000000002540</pub-id><pub-id pub-id-type="pmid">39965615</pub-id><pub-id pub-id-type="pmcid">PMC11939094</pub-id></element-citation></ref><ref id="B68-jcm-14-06241"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swaroop</surname><given-names>G.</given-names></name></person-group><article-title>Post-myocardial infarction heart failure: A review on management of drug therapies</article-title><source>Cureus</source><year>2022</year><volume>14</volume><fpage>e25745</fpage><pub-id pub-id-type="doi">10.7759/cureus.25745</pub-id><pub-id pub-id-type="pmid">35812579</pub-id><pub-id pub-id-type="pmcid">PMC9264286</pub-id></element-citation></ref><ref id="B69-jcm-14-06241"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lorusso</surname><given-names>R.</given-names></name><name name-style="western"><surname>Matteucci</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lerakis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ronco</surname><given-names>D.</given-names></name><name name-style="western"><surname>Menicanti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>P.R.</given-names></name></person-group><article-title>Postmyocardial infarction ventricular aneurysm: JACC focus seminar 5/5</article-title><source>J. Am. Coll. Cardiol.</source><year>2024</year><volume>83</volume><fpage>1917</fpage><lpage>1935</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2024.02.044</pub-id><pub-id pub-id-type="pmid">38719371</pub-id></element-citation></ref><ref id="B70-jcm-14-06241"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamas</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Flaker</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Gersh</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Basta</surname><given-names>L.</given-names></name><name name-style="western"><surname>Moy&#233;</surname><given-names>L.</given-names></name><name name-style="western"><surname>Braunwald</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pfeffer</surname><given-names>M.A.</given-names></name></person-group><article-title>Clinical significance of mitral regurgitation after acute myocardial infarction</article-title><source>Circulation</source><year>1997</year><volume>96</volume><fpage>3</fpage><pub-id pub-id-type="doi">10.1161/01.CIR.96.3.827</pub-id><pub-id pub-id-type="pmid">9264489</pub-id></element-citation></ref><ref id="B71-jcm-14-06241"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hennessey</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sabatovicz</surname><given-names>N.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Del Trigo</surname><given-names>M.</given-names></name></person-group><article-title>Acute ischemic mitral valve regurgitation</article-title><source>J. Clin. Med.</source><year>2022</year><volume>11</volume><elocation-id>5526</elocation-id><pub-id pub-id-type="doi">10.3390/jcm11195526</pub-id><pub-id pub-id-type="pmid">36233410</pub-id><pub-id pub-id-type="pmcid">PMC9571705</pub-id></element-citation></ref><ref id="B72-jcm-14-06241"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Damluji</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>van Diepen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Katz</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Menon</surname><given-names>V.</given-names></name><name name-style="western"><surname>Tamis-Holland</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Bakitas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Balsam</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Chikwe</surname><given-names>J.</given-names></name><name name-style="western"><surname>Arteriosclerosis</surname><given-names>T.C.O.</given-names></name><etal/></person-group><article-title>Mechanical complications of acute myocardial infarction: A scientific statement from the American Heart Association</article-title><source>Circulation</source><year>2021</year><volume>144</volume><fpage>e16</fpage><lpage>e35</lpage><pub-id pub-id-type="doi">10.1161/CIR.0000000000000985</pub-id><pub-id pub-id-type="pmid">34126755</pub-id><pub-id pub-id-type="pmcid">PMC9364424</pub-id></element-citation></ref><ref id="B73-jcm-14-06241"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;gAra</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Kushner</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Ascheim</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Casey</surname><given-names>D.E.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Chung</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>de Lemos</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Ettinger</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Fesmire</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Franklin</surname><given-names>B.A.</given-names></name><etal/></person-group><article-title>2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction</article-title><source>Circulation</source><year>2013</year><volume>127</volume><fpage>e362</fpage><lpage>e425</lpage><pub-id pub-id-type="doi">10.1161/CIR.0b013e3182742c84</pub-id><pub-id pub-id-type="pmid">23247304</pub-id></element-citation></ref><ref id="B74-jcm-14-06241"><label>74.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Pujari</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Agasthi</surname><given-names>P.</given-names></name></person-group><article-title>Left ventricular rupture</article-title><source>StatPearls [Internet]</source><publisher-name>StatPearls Publishing</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2025</year><pub-id pub-id-type="pmid">32644697</pub-id></element-citation></ref><ref id="B75-jcm-14-06241"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shahreyar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Akinseye</surname><given-names>O.</given-names></name><name name-style="western"><surname>Nayyar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ashraf</surname><given-names>U.</given-names></name><name name-style="western"><surname>Ibebuogu</surname><given-names>U.N.</given-names></name></person-group><article-title>Post-myocardial infarction ventricular septal defect: A comprehensive review</article-title><source>Cardiovasc. Revasc. Med.</source><year>2020</year><volume>21</volume><fpage>1444</fpage><lpage>1449</lpage><pub-id pub-id-type="doi">10.1016/j.carrev.2018.11.017</pub-id><pub-id pub-id-type="pmid">30527592</pub-id></element-citation></ref><ref id="B76-jcm-14-06241"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adler</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Charron</surname><given-names>P.</given-names></name><name name-style="western"><surname>Imazio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Badano</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bar&#243;n-Esquivias</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bogaert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brucato</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gueret</surname><given-names>P.</given-names></name><name name-style="western"><surname>Klingel</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lionis</surname><given-names>C.</given-names></name><etal/></person-group><article-title>2015 ESC Guidelines for the diagnosis and management of pericardial diseases</article-title><source>Eur. Heart J.</source><year>2015</year><volume>36</volume><fpage>2921</fpage><lpage>2964</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehv318</pub-id><pub-id pub-id-type="pmid">26320112</pub-id><pub-id pub-id-type="pmcid">PMC7539677</pub-id></element-citation></ref><ref id="B77-jcm-14-06241"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verma</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Montane</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chetrit</surname><given-names>M.</given-names></name><name name-style="western"><surname>Khayata</surname><given-names>M.</given-names></name><name name-style="western"><surname>Furqan</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Ayoub</surname><given-names>C.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>A.L.</given-names></name></person-group><article-title>Pericarditis and post-cardiac injury syndrome as a sequelae of acute myocardial infarction</article-title><source>Curr. Cardiol. Rep.</source><year>2020</year><volume>22</volume><fpage>127</fpage><pub-id pub-id-type="doi">10.1007/s11886-020-01371-5</pub-id><pub-id pub-id-type="pmid">32856192</pub-id></element-citation></ref><ref id="B78-jcm-14-06241"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Indik</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Alpert</surname><given-names>J.S.</given-names></name></person-group><article-title>Post-myocardial infarction pericarditis</article-title><source>Curr. Treat. Opt. Cardiovasc. Med.</source><year>2000</year><volume>2</volume><fpage>351</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1007/s11936-996-0009-7</pub-id><pub-id pub-id-type="pmid">11096540</pub-id></element-citation></ref><ref id="B79-jcm-14-06241"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sasse</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eriksson</surname><given-names>U.</given-names></name></person-group><article-title>Post-cardiac injury syndrome: Aetiology, diagnosis, and treatment</article-title><source>ESC E-J. Cardiol. Pract.</source><year>2017</year><volume>15</volume><fpage>21</fpage><lpage>31</lpage></element-citation></ref><ref id="B80-jcm-14-06241"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kerneis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nafee</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yee</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Kazmi</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Datta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zeitouni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Afzal</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Jafarizade</surname><given-names>M.</given-names></name><name name-style="western"><surname>Walia</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Qamar</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Most promising therapies in interventional cardiology</article-title><source>Curr. Cardiol. Rep.</source><year>2019</year><volume>21</volume><fpage>26</fpage><pub-id pub-id-type="doi">10.1007/s11886-019-1108-x</pub-id><pub-id pub-id-type="pmid">30868280</pub-id></element-citation></ref><ref id="B81-jcm-14-06241"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collins</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reith</surname><given-names>C.</given-names></name><name name-style="western"><surname>Emberson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Armitage</surname><given-names>J.</given-names></name><name name-style="western"><surname>Baigent</surname><given-names>C.</given-names></name><name name-style="western"><surname>Blackwell</surname><given-names>L.</given-names></name><name name-style="western"><surname>Blumenthal</surname><given-names>R.</given-names></name><name name-style="western"><surname>Danesh</surname><given-names>J.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>DeMets</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Interpretation of the evidence for the efficacy and safety of statin therapy</article-title><source>Lancet</source><year>2016</year><volume>388</volume><fpage>2532</fpage><lpage>2561</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)31357-5</pub-id><pub-id pub-id-type="pmid">27616593</pub-id></element-citation></ref><ref id="B82-jcm-14-06241"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ross</surname><given-names>R.</given-names></name></person-group><article-title>Atherosclerosis-an inflammatory disease</article-title><source>N. Engl. J. Med.</source><year>1999</year><volume>340</volume><fpage>115</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1056/NEJM199901143400207</pub-id><pub-id pub-id-type="pmid">9887164</pub-id></element-citation></ref><ref id="B83-jcm-14-06241"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jernberg</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hasvold</surname><given-names>P.</given-names></name><name name-style="western"><surname>Henriksson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hjelm</surname><given-names>H.</given-names></name><name name-style="western"><surname>Thuresson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Janzon</surname><given-names>M.</given-names></name></person-group><article-title>Cardiovascular risk in post-myocardial infarction patients: Nationwide real world data demonstrate the importance of a long-term perspective</article-title><source>Eur. Heart J.</source><year>2015</year><volume>36</volume><fpage>1163</fpage><lpage>1170</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehu505</pub-id><pub-id pub-id-type="pmid">25586123</pub-id></element-citation></ref><ref id="B84-jcm-14-06241"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mariani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Spaccarotella</surname><given-names>C.A.M.</given-names></name><name name-style="western"><surname>Rea</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Franzone</surname><given-names>A.</given-names></name><name name-style="western"><surname>Piccolo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Castiello</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Indolfi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Esposito</surname><given-names>G.</given-names></name></person-group><article-title>Artificial Intelligence and Its Role in the Diagnosis and Prediction of Adverse Events in Acute Coronary Syndrome: A Narrative Review of the Literature</article-title><source>Life</source><year>2025</year><volume>15</volume><elocation-id>515</elocation-id><pub-id pub-id-type="doi">10.3390/life15040515</pub-id><pub-id pub-id-type="pmid">40283070</pub-id><pub-id pub-id-type="pmcid">PMC12029043</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="jcm-14-06241-f001" orientation="portrait"><label>Figure 1</label><caption><p>Non-modifiable vs modifiable risk factors and alternative causes of MI. Created in Canva. Adapted from [<xref rid="B1-jcm-14-06241" ref-type="bibr">1</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jcm-14-06241-g001.jpg"/></fig><fig position="float" id="jcm-14-06241-f002" orientation="portrait"><label>Figure 2</label><caption><p>MI localisation with lead correlation on ECG. Created in Canva. Adapted from [<xref rid="B1-jcm-14-06241" ref-type="bibr">1</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jcm-14-06241-g002.jpg"/></fig><fig position="float" id="jcm-14-06241-f003" orientation="portrait"><label>Figure 3</label><caption><p>Initial management of patients with suspected MI. Created in Canva.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jcm-14-06241-g003.jpg"/></fig><fig position="float" id="jcm-14-06241-f004" orientation="portrait"><label>Figure 4</label><caption><p>STEMI management protocol. Created in Canva. Adapted from [<xref rid="B32-jcm-14-06241" ref-type="bibr">32</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jcm-14-06241-g004.jpg"/></fig><fig position="float" id="jcm-14-06241-f005" orientation="portrait"><label>Figure 5</label><caption><p>NSTEMI and unstable angina management protocol. Created in Canva. Adapted from [<xref rid="B32-jcm-14-06241" ref-type="bibr">32</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jcm-14-06241-g005.jpg"/></fig><fig position="float" id="jcm-14-06241-f006" orientation="portrait"><label>Figure 6</label><caption><p>Diagram of post-MI complications. Created in Canva.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jcm-14-06241-g006.jpg"/></fig></floats-group></article></pmc-articleset>